LncRNAs 表达水平与膀胱癌患者预后关系的 Meta 分析

原文： 2018 年发布于 Front Physiol 122 卷第 5 期 1298-1312  浏览量：172次

作者单位： Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan Department of Public Health, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. Electronic address: ahmed011172@med.bsu.edu.eg. Department of Public Health, Faculty of Medicine, Minia University, El-Minia, Egypt Department of Public Health and Occupational Medicine, Faculty of Health Sciences - AlQunfudah, Umm AlQura University, Meccah, Saudi Arabia. Department of Public Health, Faculty of Medicine, Minia University, El-Minia, Egypt Advanced Clinical Epidemiology, Medical Data Science, Osaka University Graduate School of Medicine, Osaka Japan.

归属分类：膀胱肿瘤治疗及预后证据

DOI： 10.3390/diagnostics12051154

关键词：膀胱肿瘤亚型分期预后 Meta分析

BACKGROUND: The relationship between vascular endothelial growth factor (VEGF) gene variant rs699947 polymorphism and urologic neoplasms risk was studied extensively in recent years. The VEGF gene plays a key role in angiogenesis of urologic neoplasms, but some conclusions are still inconclusive. The aim of this study was to determine whether this polymorphism is a risk factor for susceptibility to urologic neoplasms by conducting a meta-analysis. METHODS: We performed a meta-analysis of 15 different publications from the PubMed, Embase and Medline databases, to better assess the association between VEGF rs699947 polymorphism and urologic neoplasms risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were evaluated using random or fixed effects models. RESULTS: By pooling all eligible studies, we found that the VEGF rs699947 polymorphism was not associated with overall urologic neoplasms. However, subgroup analysis based on cancer types demonstrated that significantly increased association was found between VEGF rs699947 polymorphism and the risk of bladder cancer (BCa) under heterozygous genetic model (OR = 1.48, 95%CI = 1.17-1.89). And rs699947 polymorphism was also identified an increased risk of renal cell carcinoma (RCC) under dominant, recessive, homozygous, heterozygous and allelic contrast genetic models, while no association was observed in prostate cancer (PCa). In addition, in subgroup analysis by ethnicity, we found rs699947 polymorphism was associated with Asian population under dominant, homozygous, heterozygous and allelic contrast genetic models. No evidence of publication bias was found (Begg's test, P = 0.855; Egger's test, P = 0.590). CONCLUSIONS: In summary, our study showed evidence that the VEGF rs699947 polymorphism was obviously associated with an increased risk of bladder cancer and renal cell carcinoma, particularly in Asian population, while no significant association was observed in overall urologic neoplasms. Future studies with larger sample sizes are warranted to further evaluate these associations in more details.